en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu

Caregivers Blog

HAPPY NEW YEAR FROM ALL OF US!

HAPPY NEW YEAR FROM ALL OF US!

HAPPY NEW YEAR!! May this year increase your hope and happiness! Let’s go forward together to Defeat MSA forever! We thank you for your continued support! www.msacanada.ca/donate-to-us/ #defeatmsa #kickmsa

Lundbeck Launches Phase 2 Study for MSA

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck!  The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Alterity reports additional support for ATH 434

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

MSA BLOGS 

Advocate’s Blog

REGISTER NOW – MSA VIRTUAL FREE CONFERENCE, SEPT 24-OCT 2

REGISTER NOW – MSA VIRTUAL FREE CONFERENCE, SEPT 24-OCT 2

Defeat MSA Canada/Vaincre AMS Canada, Defeat MSA Alliance (US) and allied charities in the MSA United Consortium are pleased to announce the Second All-Community MSA Virtual Conference, Sept 24-Oct 2, 2021. This year's conference will include several exciting...

GET SOME GEAR & RAISE AWARENESS ALL YEAR LONG!

GET SOME GEAR & RAISE AWARENESS ALL YEAR LONG!

Defeat MSA Canada/Vaincre L’AMS Canada Board Member & MSA Patient Advocate Kelly Murphy tests out the new mug! Maybe a 'wee nip of something strong?  Order One Now! www.MSAcanada.ca There are also online stores for some of our affiliated MSA United charites:...

Researcher’s Blog

Lundbeck Launches Phase 2 Study for MSA

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck!  The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Alterity reports additional support for ATH 434

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

MODAG Collaboration Update – MSA Drug

MODAG Collaboration Update – MSA Drug

Congratulations to MODAG! On behalf of MSA/AMS patients around the world, we are thankful for your efforts! 💜. https://www.tevapharm.com/news-and-media/latest-news/teva-and-modag-announce-licensing-collaboration-for-neurodegenerative-disease-drug-candidate/

Patient’s Blog

You May Also Like…

English